Navigation Links
Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer
Date:3/4/2008

SOUTH SAN FRANCISCO, Calif., March 4 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, will present data at the upcoming 39th Annual Meeting on Women's Cancer hosted by the Society of Gynecologic Oncologists (SGO). This year's conference will be held March 9-12, 2008 at the Tampa Convention Center in Tampa, Fla.

Interim data from Sunesis' ongoing Phase 2 clinical trial of SNS-595 in platinum-resistant ovarian cancer will be featured in a poster, "A Phase 2 Trial of SNS-595 in Women with Platinum-Refractory Epithelial Ovarian Cancer"(Abstract # 290), beginning on Sunday, March 9, 2008. Presenting author William P. McGuire, M.D., Medical Director of the Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital, and a lead investigator for the Phase 2 trial, will be available at the poster on Tuesday, March 11, 2008 between 2:00-3:00 p.m. to discuss the interim Phase 2 data. The poster will also be available following the conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. The company's lead compound, SNS-595, is currently in a Phase 1b clinical trial in patients with acute leukemia and a Phase 2 clinical trial in patients with ovarian cancer. SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SN
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
2. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
5. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
9. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
11. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... Netherlands, May 14 Nucletron, a,knowledge-based leader ... release,of Oncentra(R) Brachy, a comprehensive film- and ... planning for brachytherapy.,Oncentra Brachy, the world,s first ... Windows-based planning system that features,state-of-the-art optimization algorithms ...
... 14 Experts from PAREXEL Consulting will present insights ... to be held May 18-21, 2009 at the Georgia ... a business unit of PAREXEL International (Nasdaq: ... and medical device industries. PAREXEL Consulting experts will be ...
... Pharmaxis (ASX: PXS;,Nasdaq: PXSL ) today announced ... Drug Administration (FDA) that the New Drug Application (NDA),for ... for,standard review. The FDA will advise the result ... Pharmaxis is seeking approval for Aridol for ...
Cached Biology Technology:Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 3PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 4U.S. FDA Accepts Aridol(TM) New Drug Application for Review 2
(Date:4/23/2014)... This news release is available in French and ... woman? Male or female? In humans and other mammals, the difference ... Y chromosome. It is present only in males, where the two ... chromosomes. Thus, the Y is ultimately responsible for all the morphological ... not always been the case. A very long time ago, the ...
(Date:4/23/2014)... People diagnosed with Huntington,s disease, most in their ... mental, physical, and behavioral decline within two decades. ... of the genetic disease, have been the primary ... But according to new research from Prof. Gerardo ... University,s Department of Cell Research and Immunology, in ...
(Date:4/23/2014)... Valley, NY. (Apr. 23 2014) A ... neural stem cells (hNSCs) into the brains of ... after 22 and 24 months found that the ... and did not cause tumors. , The study ... Cell Transplantation but is currently freely ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... Chironex species are among the most venomous animals in ... venom, though, which kills by rapidly punching holes in human ... according to research published December 12 in the open access ... University of Hawaii and colleagues. The researchers ...
... be some in that cookie? Now you can find out ... A team of researchers from the UCLA Henry Samueli School ... called the iTube, which attaches to a common cell phone ... the cell phone,s built-in camera, along with an accompanying smart-phone ...
... the Great Lakes, including phosphorus-rich Lake Erie, is an age-old ... of scientists, including Mercyhurst University biologist Steven Mauro, Ph.D. ... avian botulism are linked to Cladophora and scientific ... renewed attention in the nuisance algae. For Mauro, whose ...
Cached Biology News:Got food allergies? Thanks to UCLA, you can test your meal on the spot using a cell phone 2Got food allergies? Thanks to UCLA, you can test your meal on the spot using a cell phone 3Grant furthers Mercyhurst research for human pathogens in Great Lakes 2
...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... siRNA Custom Synthesis Service provides ... RNA to knockdown any gene. ... RNA base pairs with terminal ... or other lengths of your ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: